Assembly Biosciences Inc (ASMB) Director Sells $49,370.00 in Stock

Assembly Biosciences Inc (NASDAQ:ASMB) Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $49.37, for a total value of $49,370.00. Following the transaction, the director now directly owns 20,465 shares of the company’s stock, valued at $1,010,357.05. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Assembly Biosciences Inc (NASDAQ:ASMB) traded down $0.02 during mid-day trading on Thursday, hitting $44.10. The stock had a trading volume of 136,300 shares, compared to its average volume of 91,169. Assembly Biosciences Inc has a 1 year low of $11.07 and a 1 year high of $52.37.

Several hedge funds have recently bought and sold shares of ASMB. State Street Corp bought a new position in shares of Assembly Biosciences in the 2nd quarter worth about $4,234,000. JPMorgan Chase & Co. bought a new position in shares of Assembly Biosciences in the 2nd quarter worth about $3,426,000. Valeo Financial Advisors LLC bought a new position in shares of Assembly Biosciences in the 3rd quarter worth about $4,963,000. Northern Trust Corp raised its position in shares of Assembly Biosciences by 221.2% in the 2nd quarter. Northern Trust Corp now owns 195,321 shares of the biopharmaceutical company’s stock worth $4,033,000 after acquiring an additional 134,513 shares in the last quarter. Finally, AXA bought a new position in shares of Assembly Biosciences in the 2nd quarter worth about $2,477,000. 62.09% of the stock is owned by hedge funds and other institutional investors.

Several research analysts recently issued reports on the company. BidaskClub lowered Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Zacks Investment Research lowered Assembly Biosciences from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Chardan Capital reaffirmed a “buy” rating on shares of Assembly Biosciences in a research report on Sunday, September 17th. Finally, Jefferies Group began coverage on Assembly Biosciences in a research report on Wednesday, November 8th. They issued a “buy” rating and a $50.00 price objective for the company.

WARNING: This report was originally reported by Stock Observer and is the property of of Stock Observer. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.thestockobserver.com/2017/12/07/assembly-biosciences-inc-asmb-director-sells-49370-00-in-stock.html.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Receive News & Ratings for Assembly Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply